If you have been reading about GHRH receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
=== Effect on nutrients and sensory quality === Due to the low processing temperatures and the minimization of deterioration reactions, nutrients are retained and color is maintained. Freeze-dried fruit maintains its original shape and has a characteristic soft crispy texture.
=== Iranian IRGC involvement === In 2013, an Iranian vessel was seized and discovered to be carrying Katyusha rockets, heat-seeking surface-to-air missiles, RPG-7s, Iranian-made night vision goggles and artillery systems that track land and navy targets 40 km away. That was en route to the Houthis. In March 2017, Qasem Soleimani, head of Iran's Quds Force, met with Iran's Islamic Revolutionary Guard Corps (IRGC) regarding the "newly accelerated effort to empower the Houthis", including the provision of weapons and training. Soleimani was quoted as saying, "At this meeting, they agreed to increase the amount of help, through training, arms and financial support." Despite the Iranian government, and Houthis both officially denying Iranian support for the group. Brigadier General Ahmad Asiri, the spokesman of the Saudi-led coalition told Reuters that evidence of Iranian support was manifested in the Houthi use of Kornet anti-tank guided missiles which had never been in use with the Yemeni military or with the Houthis and that the arrival of Kornet missiles had only come at a later time. In the same month the IRGC had altered the routes used in transporting equipment to the Houthis by spreading out shipments to smaller vessels in Kuwaiti territorial waters in order to avoid naval patrols in the Gulf of Oman due to sanctions imposed, shipments reportedly included parts of missiles, launchers, and drugs.
== Science, technology and mathematics == Central limit theorem, in probability and statistics Construal level theory, a statistical social theory Central location test, a marketing research technique Cross-laminated timber, an engineered wood
=== Clinical trials === Retatrutide has been studied in a phase 2 trial involving adults without diabetes but with obesity or preobesity (overweight). Retatrutide is also being evaluated in phase 3 clinical trials. Two trials in the phase 3 TRIUMPH program reached primary completion in April 2026: TRIUMPH-1, a master protocol in adults with obesity or overweight, and TRIUMPH-3, in participants with severe obesity and established cardiovascular disease. A substudy in adults with type 2 diabetes reported differences in total body fat mass between study groups at 36 weeks. Preclinical and biochemical studies describe receptor activity at GLP-1, GIP, and glucagon receptors. Reports on its development state that it was engineered for activity across these targets. Systematic reviews and meta-analyses of randomized controlled trials report that retatrutide produces substantial reductions in body weight in adults with obesity, with mean percentage weight loss typically between 15 and 24 percent over 48 to 72 weeks, depending on study protocols and populations. Adverse events are most commonly gastrointestinal symptoms such as nausea and diarrhea, with relatively low rates of study discontinuation and infrequent serious adverse events reported during trials. Safety assessments also indicate a low risk of hypoglycemia and no significant elevation in cardiovascular or hepatic adverse events in non-diabetic populations across published studies.
Intranasal administration of naloxone via nasal spray has likewise been found to rapidly occupy brain MORs, with peak occupancy occurring at 20 minutes, peak occupancies of 67% at a dose of 2 mg and 85% with 4 mg, and an estimated half-life of occupancy disappearance of approximately 100 minutes (1.67 hours).
Sources: en.wikipedia.org
Russell Findlay, leader of the Scottish Conservatives, says he will not attend a forthcoming anti-far-right summit being chaired by First Minister of Scotland John Swinney, saying the event is "not required" and is being used to "deflect from the SNP's dismal record". 20 April – Yvette Cooper condemns the vandalism of statues in Parliament Square during a transgender rights protest. 22 April – The Department for Business and Trade announces that the proposed redundancies at British Steel will not continue. Kemi Badenoch calls for the ban of recording "non-crime hate incidents". Deborah Taylor is announced as the chair of the public inquiry into the 2023 Nottingham attacks. The Scottish Government says it has no plans to bring back the Gender Recognition Reform (Scotland) Bill following the Supreme Court ruling on what defines a woman. Russell George withdraws as a Conservative candidate for the 2026 Senedd election after being charged over the general election betting scandal. 23 April – Kemi Badenoch rejects claims of a rift with Conservative frontbencher Robert Jenrick over whether the party should form a coalition with Reform UK after Sky News obtained footage of him speaking about wanting to "unite" the "fight" against Labour at the next general election. 24 April – Campaign group Hope Not Hate says that Reform UK is fielding local election candidates who have "posted hate, pushed far-right conspiracies and praised extremists" despite statements by Nigel Farage about improving the party's vetting process.
==== 1950–1999 ==== In 1951, Feuchtwanger initiated an initial public offering to raise capital through the newly founded Tel-Aviv Stock Exchange and Teva became a public company. In 1954, Teva received a Certificate Excellence in Training award from the Israeli President, Yitzhak Ben Zvi. In 1964, Teva partnered with Sintex, a company from Mexico, and Schering Plough. In 1964, Assia and Zori merged and in 1968 acquired a controlling stake in Teva. In 1976, the three companies merged into the modern-day Teva Pharmaceutical Industries Ltd. In 1980, Teva acquired Ikapharm, then Israel's second largest drug manufacturer. In 1980, Teva acquired Plantex. In 1982, Teva was granted approval by the U.S. Food and Drug Administration (FDA) for its Kfar Saba manufacturing plant. In 1995, Teva acquired Biogal Gyógyszergyár Rt. (Debrecen, Hungary) and acquired ICI (Italy).
=== Other uses === Fumaric acid is used in the manufacture of polyester resins and polyhydric alcohols and as a mordant for dyes. Fumaric acid can be used to make 6-methylcoumarin. When fumaric acid is added to their feed, lambs produce up to 70% less methane during digestion.
=== Background === Influenced by strategic analyses such as the 1976 Team B report—which argued U.S. intelligence had vastly underestimated Soviet threats—and ideas of the Citizens' Advisory Council on National Space Policy, President Ronald Reagan announced the Strategic Defense Initiative (SDI) in 1983. It proposed a space-based global missile defense constellation intended to render nuclear weapons "impotent and obsolete." The program immediately faced challenges, with concerns by Congress, including prominent senators Sam Nunn and Joe Biden, over its apparent violation of the Anti-Ballistic Missile Treaty, questionable technical feasibility, spiraling launch costs, poor cost-exchange ratio, and destabilizing impact on arms control. By the 1990s, SDI was formally restructured into the Ballistic Missile Defense Organization, pivoting from space-based platforms to more proven ground- and sea-based systems. U.S. missile defense policy continued to evolve, with the 1999 National Missile Defense Act mandating a system to defend against limited ballistic missile attacks. Following a later Team B report's recommendation, President George W. Bush withdrew the U.S. from the ABM Treaty in 2001. The Obama administration's 2010 Review shifted focus from a homeland-centered shield to more flexible and cooperative regional defenses, limiting the space component to sensing and tracking. This was adjusted by the Trump administration's 2019 Review, expanding scope from rogue states such as North Korea, to include advanced hypersonic threats from "competitors" like Russia and China.
== History == The existence of the ribosomal tunnel became apparent in the 1960s. When the nascent protein was exposed to hydrolytic enzymes, part of the protein was protected from hydrolysis, supporting the hypothesis of the existence of a tunnel that shields part of the protein. The tunnel was then identified in the large subunit of the ribosome by cryogenic electron microscopy. Crucial information about the existence of the tunnel was provided by atomically resolved structures of the large ribosomal subunit determined by X-ray crystallography by the research group of Thomas Steitz. In 2009, Thomas Steitz, along with A. Yonath and V. Ramakrishnan, received the Nobel Prize in Chemistry for their research on the ribosome. The initial view that the tunnel is merely an inert environment through which the nascent polypeptide exits the ribosome has been abandoned based on numerous studies. Today, it is believed that the tunnel is actively involved in regulating translation and maintaining homeostasis.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.